M. D. Grmek, Les idées de Descartes sur le prolongement de la vie et le mécanisme du vieillissement. Revue d'histoire des sciences et de leurs applications, vol.21, pp.285-302, 1968.
DOI : 10.3406/rhs.1968.2566

URL : http://www.persee.fr/docAsPDF/rhs_0048-7996_1968_num_21_4_2566.pdf

J. Guevara-aguirre, P. Balasubramanian, M. Guevara-aguirre, M. Wei, F. Madia et al., Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans, 2011.

, Science Translational Medicine, vol.3, issue.70, pp.70-83

D. E. Harrison, R. Strong, Z. D. Sharp, J. F. Nelson, C. M. Astle et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice, Nature, vol.460, issue.7253, pp.392-397, 2009.

M. Holzenberger, J. Dupont, B. Ducos, P. Leneuve, A. Géloën et al., IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice, Nature, issue.6919, p.182, 2003.
URL : https://hal.archives-ouvertes.fr/hal-01939325

D. K. Ingram and R. De-cabo, Calorie restriction in rodents: Caveats to consider, Ageing research reviews, vol.39, pp.15-28, 2017.

, Major Mouse crowdfunding, 2014.

O. R. Jones, A. Scheuerlein, R. Salguero-gómez, C. G. Camarda, R. Schaible et al., Diversity of ageing across the tree of life, Nature, issue.7482, p.169, 2014.

M. Kaeberlein, The genetics of ageing, The Biology of Aging: Citizen Scientists and Their Pets as a Bridge Between Research on Model Organisms and Human Subjects, vol.464, p.504, 2010.

R. Lee and L. Carter, Journal of the American Statistical Association, vol.87, 1992.

R. D. Macminn and N. Zhu, Hedging Longevity Risk in Life Settlements Using Biomedical ResearchBacked Obligations, Journal of Risk and Insurance, vol.84, issue.1, pp.439-458, 2017.

J. P. De-magalhães, M. Stevens, and D. Thornton, The business of anti-aging science, Trends in biotechnology, 2017.

S. Makin, Fountain of Youth? Young Blood Infusions "Rejuvenate" Old Mice, 2017.

J. B. Mannick, D. Giudice, G. Lattanzi, M. Valiante, N. M. Praestgaard et al., mTOR inhibition improves immune function in the elderly, Sci Transl Med, 2014.

, , vol.6, pp.268-179

A. Mortalite,

A. Martin-montalvo, E. M. Mercken, S. J. Mitchell, H. H. Palacios, P. L. Mote et al., Metformin improves healthspan and lifespan in mice, vol.4, p.2192, 2013.

R. Martins, G. J. Lithgow, and W. Link, Long live FOXO: unraveling the role of FOXO proteins in aging and longevity, Aging cell, vol.15, issue.2, pp.196-207, 2016.

C. M. Mccay and M. F. Crowell, Prolonging the life span, The Scientific Monthly, vol.39, issue.5, pp.405-414, 1934.

J. Mellon and A. Chalabi, Juvenescence: Investing in the age of longevity, 2017.

T. A. Mir and M. Nakamura, Three-Dimensional Bioprinting: Toward the Era of Manufacturing Human Organs as Spare Parts for Healthcare and Medicine, Tissue Eng Part B Rev, vol.23, issue.3, pp.245-256, 2017.

J. Mitteldorf, Tomorrow's Anti-Aging Therapy, Available Today (BioViva), 2015.

, Josh Mitteldorf's Aging Blog

A. Moskalev, V. Anisimov, A. Aliper, A. Artemov, K. Asadullah et al., A review of the biomedical innovations for healthy longevity, vol.9, pp.7-25, 2017.

J. Most, V. Tosti, L. M. Redman, and L. Fontana, Calorie restriction in humans: an update, Ageing research reviews, vol.39, pp.36-45, 2017.

L. Mosteiro, C. Pantoja, A. Martino, and M. Serrano, Senescence promotes in vivo reprogramming through p16INK4a and IL6. Aging cell, 2017.

L. T. Ng, J. Gruber, and P. K. Moore, Is there a role of H 2 S in mediating health span benefits of caloric restriction? Biochemical pharmacology, 2018.

A. Ocampo, P. Reddy, P. Martinez-redondo, A. Platero-luengo, F. Hatanaka et al., Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming, vol.167, pp.1719-1733, 2016.

J. Oeppen and J. Vaupel, Broken Limits to Life Expectancy, Science, vol.296, 2002.

A. Mortalite,

S. J. Olshansky, B. A. Carnes, and C. Cassel, Search of Methuselah: Estimating the Upper Limits to Human Longevity, vol.250, p.4981, 1990.

F. Pietrocola, F. Castoldi, M. Markaki, S. Lachkar, G. Chen et al., Aspirin Recapitulates Features of Caloric Restriction, vol.22, pp.2395-2407, 2018.

F. Pifferi, J. Terrien, J. Marchal, A. Dal-pan, F. Djelti et al., Caloric restriction increases lifespan but affects brain integrity in grey mouse lemur primates, Communications Biology, vol.1, issue.1, p.30, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01912059

G. Pison, France 2004 : l'espérance de vie franchit le seuil de 80 ans, p.410, 2005.

. Populationdata,

C. Pratt, 5 Private Longevity Stocks to Watch: From Calico to Genescient, 2016.

J. D. Rauh, Hidden debt, hidden deficits, 2016.

D. J. Ravnic, A. N. Leberfinger, S. V. Koduru, M. Hospodiuk, K. K. Moncal et al., Transplantation of Bioprinted Tissues and Organs: Technical and Clinical Challenges and Future Perspectives, Ann Surg, vol.266, issue.1, pp.48-58, 2017.

. Rescueelders, , 2018.

J. M. Robine and S. Cheung, Nouvelles observations sur la longévité humaine. Revue économique, vol.59, pp.941-953, 2008.

P. Román and A. Ruiz-cantero, Polypathology, an emerging phenomenon and a challenge for healthcare systems, Rev Clin Esp, vol.217, issue.4, pp.229-237, 2017.

D. Shytikov, O. Balva, E. Debonneuil, P. Glukhovskiy, and I. Pishel, Aged mice repeatedly injected with plasma from young mice: a survival study, vol.3, pp.226-232, 2014.

I. Stambler, A History of Life-extensionism in the Twentieth Century, Interdisciplinary Studies Unit. Science, Technology and Society, 2011.

R. M. Stein, A Simple Hedge for Longevity Risk and Reimbursement Risk Using Research-Backed Obligations, MIT Sloan Research Paper, pp.5165-5181, 2016.

R. Strong, R. A. Miller, C. M. Astle, R. A. Floyd, K. Flurkey et al., Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice, Aging Cell, vol.7, issue.5, pp.641-650, 2008.

U. Thiem, T. Hinrichs, C. A. Müller, S. Holt-noreiks, A. Nagl et al., Prerequisites for a new health care model for elderly people ANALYSES PROSPECTIVES DE MORTALITE : APPROCHES ACTUARIELLE ET BIOMEDICALE CONCLUSION ET REFERENCES BIBLIOGRAPHIQUES 82 with multiple morbidities: results and conclusions from 3 years of research in the PRISCUS consortium, Z Gerontol Geriatr, vol.44, issue.2, pp.101-113, 2011.

. Transparency-market-research, Anti-aging Market (Anti-wrinkle products, Hair Color, Hair restoration treatment, Breast augmentation and Radio frequency devices)-Global Industry Analysis, Size, Share, Growth, Trends and Forecast, pp.2013-2019, 2014.

. Tribune-de-genève, , 2016.

J. Vallin and F. Meslé, Espérance de vie: peut-on gagner trois mois par an indéfiniment ?, p.473, 2010.

S. A. Villeda, J. Luo, K. I. Mosher, B. Zou, M. Britschgi et al., The ageing systemic milieu negatively regulates neurogenesis and cognitive function, vol.477, p.90, 2011.

. Willis-towers-watson, Global Pensions Assets Study, 2017.

X. Yang, E. Debonneuil, A. Zhavoronkov, and B. Mishra, Cancer megafunds with in silico and in vitro validation: Accelerating cancer drug discovery via financial engineering without financial crisis, Oncotarget, 2016.

L. Ye, A. L. Widlund, C. A. Sims, D. W. Lamming, Y. Guan et al., Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance, Aging, vol.5, issue.7, pp.539-50, 2013.

A. Zhavoronkov, E. Debonneuil, N. Mirza, and I. Artyuhov, Evaluating the impact of recent advances in biomedical sciences and the possible mortality decreases on the future of health care and Social Security in the United States. Pensions, vol.17, pp.241-251, 2012.

A. Zhavoronkov, Anti-Aging Market (Baby Boomer, Generation X and Generation Y), by product (Botox, Anti-Wrinkle Products, Anti-Stretch Mark Products, and Others), by Services (Anti-Pigmentation Therapy, Anti-Adult Acne Therapy, Breast Augmentation, Liposuction, Chemical Peel, Hair Restoration Treatment, and Others), by Device (Microdermabrasion, Laser Aesthetics, AntiCellulite Treatment and Anti-Aging Radio Frequency Devices) : Global Industry Perspective, The Ageless Generation : How Advances in Biomedicine Will Transform the Global Economy, pp.2015-2021, 2013.

, David Gems 17 , Vadim Gladyshev 18 , Vera Gorbunova 19, Joao Pedro de Magalhaes, vol.10, issue.9, pp.28-45, 2007.

W. C. Buijs, J. G. Tibben, and O. C. Boerman, Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration, Eur J Nucl Med, vol.25, pp.1552-1561, 1998.

A. Carrel and A. H. Ebeling, Age and multiplication of fibroblasts, J Exp Med, vol.34, pp.599-623, 1921.

L. Chen, X. Yang, and G. Huang, Platelet-rich plasma promotes healing of osteoporotic fractures, Orthopedics, vol.36, pp.687-694, 2013.

M. Cheng, V. M. Johnson, and M. M. Murray, Effects of age and platelet-rich plasma on ACL cell viability and collagen gene expression, J Orthop Res, vol.30, pp.79-85, 2012.

I. M. Conboy, M. J. Conboy, and A. J. Wagers, Rejuvenation of aged progenitor cells by exposure to a young systemic environment, Nature, vol.433, pp.760-764, 2005.

M. J. Conboy, I. M. Conboy, and T. A. Rando, Heterochronic parabiosis: historical perspective and methodological considerations for studies of aging and longevity, Aging Cell, vol.12, pp.525-530, 2013.

V. L. Davis, A. B. Abukabda, and N. M. Radio, Platelet-rich preparations to improve healing. Part I: Workable options for every size practice, J Oral Implantol, 2012.

S. Dou, M. Smith, and Y. Wang, Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy, Cancer Biother Radiopharmaceut, vol.28, pp.335-342, 2013.

B. Gibney, K. Chamoto, and G. S. Lee, Cross-circulation and cell distribution kinetics in parabiotic mice, J Cell Physiol, vol.227, pp.821-828, 2012.

, La mort de la mort, References Alexandre L, 2011.

P. Antolin and H. Blommestein, Governments and the Market for Longevity-Indexed Bonds. Organisation for Economic Cooperation and Development Working Papers on Insurance and Private Pensions, 2007.

P. Antolin and J. Mosher, Mortality Assumptions and Longevity Risk. Working Party on Private Pensions, 2014.

S. Arnold, A. Boumezoued, L. Hardy, H. , E. Karoui et al., Cause-of-Death mortality: What Can Be Learned From Population Dynamics? <hal-01157900>, 2015.

C. A. Bannister, S. E. Holden, S. Jenkins-jones, C. L. Morgan, J. P. Halcox et al., Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls, Diabetes Obes Metab, 2014.

J. Barbarin, Heath-Jarrow-Morton Modelling of Longevity Bonds and the Risk Minimization of Life Insurance Portfolios, vol.43, pp.41-55, 2008.

P. Barrieu, H. Bensusan, E. Karoui, N. Hillairet, C. Loisel et al., Understanding, Modeling and Managing Longevity Risk: Key Issues and Main Challenges, Scandinavian Actuarial Journal, vol.3, pp.203-231, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00417800

A. Bartke, M. Bonkowski, and M. Masternak, How diet interacts with longevity genes. Hormones, vol.7, pp.17-23, 2008.

D. Bauer, M. Börger, and J. Ru?, On the Pricing of Longevity-Linked Securities, vol.46, pp.139-149, 2010.

J. R. Beard, S. Biggs, D. E. Bloom, L. P. Fried, P. Hogan et al., Global Population Ageing: Peril or Promise? World Economic Forum. ANNEXE 3. ARTICLE: DO ACTUARIES BELIEVE IN LONGEVITY DECELERATION?-144, 2011.

J. B. Bernardes-de, E. Vera, K. Schneeberger, A. M. Tejera, E. Ayuso et al., Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer, EMBO Mol Med, vol.4, pp.691-704, 2012.

J. Bongaarts, Long-Range Trends in Adult Mortality: Models and Projections Methods. Population Council, p.192, 2014.

D. Blake, T. Boardman, and A. Cairns, Sharing Longevity Risk: Why Governments Should Issue Longevity Bonds, North American Actuarial Journal, vol.18, issue.1, pp.258-277, 2014.

D. Blake, A. Cairns, K. Dowd, and R. Macminn, Longevity Bonds: Financial Engineering, Valuation and Hedging, Journal of Risk and Insurance, vol.73, pp.647-72, 2006.

N. Brouhns, M. Denuit, and J. Vermunt, A Poisson log-bilinear regression approach to the construction of projected lifetables, Insurance: Mathematics and Economics, vol.31, pp.373-393, 2002.

S. Bulterijs, R. S. Hull, B. Vc, and A. G. Roy, It is time to classify biological aging as a disease, Front Genet, vol.6, p.205, 2015.

A. Cairns, D. Blake, K. Dowd, G. D. Coughlan, D. Epstein et al., Mortality density forecasts: An analysis of six stochastic mortality models, Insurance: Mathematics and Economics, vol.48, pp.355-367, 2011.

A. Cairns, D. Blake, K. Dowd, G. D. Coughlan, D. Epstein et al., A Quantitative comparison of stochastic mortality models using data from England and Wales and the United States, 2007.

A. Cairns, D. Blake, K. Dowd, and R. Kallestrup-lamb, Multi-population modelling: a Danish case study. Talk at the Longevity 11 conference, 2015.

C. Hayden and E. , Pet dogs set to test anti-ageing drug, Nature, vol.514, issue.7524, 2014.

D. Coeurnelle, Et si on arrêtait de vieillir! : Réalité, enjeux et perspectives d'une vie en bonne santé beaucoup plus longue, 2013.

, Conseil d'Orientation des Retraites, 2013.

G. D. Coughlan, M. Khalaf-allah, Y. Ye, S. Kumar, A. Cairns et al., Longevity Hedging 101: A Framework for Longevity Basis Risk Analysis and Hedge Effectiveness, North American Actuarial Journal, vol.15, pp.150-176, 2011.

S. H. Cox and L. Y. , Natural Hedging of Life and Annuity Mortality Risks, vol.11, pp.1-15, 2007.

J. C. Croix, F. Planchet, and P. E. Thérond, Mortality : a statistical approach to detect model misspecification, 2015.
URL : https://hal.archives-ouvertes.fr/hal-00839339

J. Cuzick, M. A. Thorat, C. Bosetti, P. H. Brown, J. Burn et al., Estimates of benefits and harms of prophylactic use of aspirin in the general population, Ann Oncol, 2014.

E. Debonneuil, L. He, J. Mosher, and N. Weiss, Longevity Risk: Setting the scene. Riskbooks ANNEXE 3. ARTICLE: DO ACTUARIES BELIEVE IN LONGEVITY DECELERATION?-145, 2011.

L. I. Dublin, Health and Wealth. A Survey of the Economics of World Health, p.361, 1928.

D. E. Fagnan, J. M. Fernandez, A. W. Lo, and R. M. Stein, Can financial engineering cure cancer?, The American Economic Review, vol.103, pp.406-411, 2013.

G. M. Fahy, Apparent induction of partial thymic regeneration in a normal human subject: a case report, J Anti-Aging Med, vol.6, issue.3, pp.219-227, 2003.

J. M. Fernandez, R. M. Stein, and A. W. Lo, Commercializing biomedical research through securitization techniques, Nature biotechnology, vol.30, pp.964-975, 2012.

E. L. Forget, The Town with No Poverty: The Health Effects of a Canadian Guaranteed Annual Income Field Experiment, Canadian Public Policy, vol.37, issue.3, 2011.

D. Gems, What is an anti-aging treatment?, Experimental Gerontology, vol.58, pp.14-18, 2014.

A. De-grey, Ask Aubrey de Grey Anything! Reddit online exchange, 2015.

A. De-grey, Escape Velocity: Why the Prospect of Extreme Human Life Extension Matters Now, PLoS Biol, vol.2, issue.6, pp.723-726, 2004.

J. Guevara-aguirre, P. Balasubramanian, M. Guevara-aguirre, M. Wei, F. Madia et al., Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans, Science Translational Medicine, vol.3, issue.70, pp.70-83, 2011.

D. E. Harrison, R. Strong, Z. D. Sharp, J. F. Nelson, C. M. Astle et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice, Nature, vol.460, issue.7253, pp.392-397, 2009.

E. C. Hayden, Anti-ageing pill pushed as bona fide drug. Regulators asked to consider ageing as a treatable condition, Nature, vol.522, pp.265-266, 2015.

, Available at www.mortality.org (data downloaded on, 2015.

A. Hunt and B. D. , Modelling Longevity Bonds: Analysing the Swiss Re Kortis Bond, vol.63, pp.12-29, 2015.

M. Kaeberlein, The Biology of Aging: Citizen Scientists and Their Pets as a Bridge Between Research on Model Organisms and Human Subjects, 2015.

A. Kogure and Y. Kurachi, A Bayesian Approach to Pricing Longevity Risk Based on Risk-Neutral Predictive Distributions, vol.46, pp.162-172, 2010.

M. Lane, Longevity Risk from the Perspective of the ILS Markets, Geneva Papers on Risk and Insurance-Issues and Practice, vol.36, pp.501-515, 2011.

, ANNEXE 3. ARTICLE: DO ACTUARIES BELIEVE IN LONGEVITY DECELERATION?-146

R. Lee and L. Carter, Journal of the American Statistical Association, vol.87, 1992.

N. Li, R. Lee, and P. Gerland, Extending the Lee-carter method to model the rotation of age patterns of mortality decline for long-term projections, Demography, vol.50, issue.6, p.23904392, 2013.

J. B. Mannick, D. Giudice, G. Lattanzi, M. Valiante, N. M. Praestgaard et al., mTOR inhibition improves immune function in the elderly, Sci Transl Med, vol.6, issue.268, pp.268-179, 2014.

A. Martin-montalvo, E. M. Mercken, S. J. Mitchell, H. H. Palacios, P. L. Mote et al., Metformin improves healthspan and lifespan in mice, vol.4, p.2192, 2013.

J. Mitteldorf, Tomorrow's Anti-Aging Therapy, Available Today (BioViva). Josh Mitteldorf's Aging Blog, 2015.

A. Ngai and M. Sherris, Longevity Risk Management for Life and Variable Annuities: The Effectiveness of Static Hedging using Longevity Bonds and Derivatives, Insurance: Mathematics and Economics, vol.49, pp.100-114, 2011.

J. Oeppen and J. Vaupel, Broken Limits to Life Expectancy, Science, vol.296, 2002.

A. Olivieri and E. Pitacco, Assessing the Cost of Capital for Longevity Risk, Insurance: Mathematics and Economics, vol.42, pp.1013-1021, 2008.

F. Planchet, Tables de mortalité d'expérience pour les portefeuilles de rentiers (Tables TGH 05 et TGF 05). Note méthodologique de l'Institut des Actuaires, 2006.

A. Richter and F. Weber, Mortality-Indexed Annuities: Managing Longevity Risk via Product Design, North American Actuarial Journal, vol.15, pp.212-236, 2011.

Y. Salhi and S. Loisel, Basis risk modelling: a co-integration based approach, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00746859

R. Strong, R. A. Miller, C. M. Astle, R. A. Floyd, K. Flurkey et al., Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice, Aging Cell, vol.7, issue.5, pp.641-650, 2008.

J. Vallin and F. Meslé, Espérance de vie: peut-on gagner trois mois par an indéfiniment ?, p.473, 2010.

J. W. Vaupel, Biodemography of human ageing, Nature, vol.464, pp.536-542, 2010.

, World Health Statistics, 2015.

L. Ye, A. L. Widlund, C. A. Sims, D. W. Lamming, Y. Guan et al., Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance, Aging, vol.5, issue.7, pp.539-50, 2013.

, ANNEXE 3. ARTICLE: DO ACTUARIES BELIEVE IN LONGEVITY DECELERATION?-147

C. Wan and L. Bertschi, Swiss Coherent Mortality Model as a Basis for Developing Longevity DeRisking Solutions for Swiss Pension Funds: A Practical Approach, Insurance: Mathematics and Economics, vol.63, pp.66-75, 2015.

J. L. Wang, M. Hsieh, and Y. Chiu, Using Reverse Mortgages to Hedge Longevity and Financial Risks for Life Insurers: A Generalized Immunization Approach, Geneva Papers on Risk and InsuranceIssues and Practice, vol.36, pp.697-717, 2011.

X. Yang, E. Debonneuil, A. Zhavoronkov, and B. Mishra, Cancer megafunds with in silico and in vitro validation: Accelerating cancer drug discovery via financial engineering without financial crisis, Oncotarget, 2016.

A. Zhavoronkov, E. Debonneuil, N. Mirza, and I. Artyuhov, Evaluating the impact of recent advances in biomedical sciences and the possible mortality decreases on the future of health care and Social Security in the United States. Pensions, vol.17, pp.241-251, 2012.

R. And-notes-ayyadevara, S. Alla, R. Thaden, J. J. Shmookler-reis, and R. J. , Remarkable longevity and stress resistance of nematode PI3K-null mutants, Ageing Cell, vol.7, issue.1, pp.13-22, 2008.

A. Bartke and H. Brown-borg, Life extension in the dwarf mouse, Current Topics in Developmental Biology, vol.63, pp.189-225, 2004.

D. Bloom, D. Canning, and G. Fink, Implications of Population Aging for Economic Growth, National Bureau of Economic Research Working Paper, issue.16705, pp.1-36, 2011.

J. Brown, R. Clark, J. Rauh, V. Engelhardt, and J. Gruber, Social Security and the Evolution of Elderly Poverty, National Bureau of Economic Research Working Paper, vol.10, issue.2, pp.1-44, 2004.

E. Debonneuil, KEHLY: European initiative to know effects on healthy life years, 2012.

H. Fullerton, Labor force 2006: Slowing down and changing composition, Monthly Labor Review, vol.11, pp.23-38, 1997.

J. Gokhale and K. Smetters, Fiscal and Generational Imbalances: New Budget Measures for New Budget Priorities. Federal Reserve Bank of Cleveland Policy Discussion Paper 5, pp.1-44, 2003.

J. Gokhale and K. Smetters, Measuring Social Security's Financial Problems, National Bureau of Economic Research Working Paper, issue.11060, pp.1-29, 2005.

B. Hamilton, A systematic RNAi screen for longevity genes in C. Elegans, 2005.
DOI : 10.1101/gad.1308205

URL : http://genesdev.cshlp.org/content/19/13/1544.full.pdf

, Genes & Development, vol.19, issue.13, pp.1544-1555

D. Harrison, Rapamycin fed late in life extends lifespan in genetically heterogeneous mice, Nature, vol.460, issue.7253, pp.392-395, 2009.

, Human Mortality Database (HMD). website at www.mortality.org where national mortality data are republished for a large number of countries

C. J. Kenyon, The genetics of ageing, Nature, vol.464, issue.7288, pp.504-512, 2010.

L. Kotlikoff, Is the United States bankrupt? Federal Reserve Bank of, St Louis Review, vol.88, issue.4, pp.235-249, 2006.

R. D. Lee and L. Carter, Modeling and forecasting U.S. mortality, Journal of the American Statistical Association, vol.87, pp.659-671, 1992.

G. M. Martin, K. Lamarco, E. Strauss, and K. L. Kelner, Research on aging: The end of the beginning, Science, vol.299, issue.5611, pp.1339-1341, 2003.

, ANNEXE 4. ARTICLE: EVALUATING THE IMPACT OF RECENT ADVANCES IN BIOMEDICAL SCIENCES AND THE POSSIBLE MORTALITY DECREASES ON THE FUTURE OF HEALTH CARE AND SOCIAL SECURITY IN THE USA-161

G. Sanz and V. Fuster, Fixed-dose combination therapy and secondary cardiovascular prevention: Rationale, selection of drugs and target population, Nature Clinical Practice Cardiovascular Medicine, vol.6, issue.2, pp.101-110, 2009.

, The OASDI Trustees Report. Board of Trustees of the Federal Old-Age and Survivors Insurance and Federal Disability Insurance Trust Funds, pp.1-252, 2012.

K. Somerville and P. Francombe, Modeling disease elimination, Journal of Insurance Medicine, vol.37, issue.1, pp.13-19, 2005.

N. J. Wald and M. R. Law, A strategy to reduce cardiovascular disease by more than 80%, BMJ, vol.326, issue.7404, p.1419, 2003.

D. S. Wald, J. K. Morris, and N. J. Wald, Randomized polypill crossover trial in people aged 50 and over, PLoS One, vol.7, issue.7, p.41297, 2012.

U. Zeymer, Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach, Current Medical Research & Opinion, vol.27, issue.8, pp.1563-1570, 2011.

A. Zhavoronkov and C. R. Cantor, ): e22597. REFERENCES Akerlof G. The market for lemons: Quality uncertainty and the market mechanism, PLoS ONE, vol.6, issue.7, 1995.

S. Arora, B. Barak, M. Brunnermeier, and R. Ge, Computational complexity and information asymmetry in financial products, Communications of the ACM, vol.54, pp.101-107, 2011.

F. H. Boissel, The cancer megafund: mathematical modeling needed to gauge risk, Nature biotechnology, vol.31, pp.494-494, 2013.

T. M. Errington, E. Iorns, W. Gunn, F. E. Tan, J. Lomax et al., An open investigation of the reproducibility of cancer biology research, The American Economic Review, vol.3, pp.406-411, 2013.

D. E. Fagnan, A. A. Gromatzky, R. M. Stein, J. M. Fernandez, and A. W. Lo, Financing drug discovery for orphan diseases. Drug discovery today, vol.19, pp.533-538, 2014.

J. M. Fernandez, R. M. Stein, and A. W. Lo, Commercializing biomedical research through securitization techniques, Nature biotechnology, vol.30, pp.964-975, 2012.

R. D. Macminn and N. Zhu, Hedging longevity risk in life settlements using biomedical rbos. Tenth International Longevity Risk and Capital Markets Solutions Conference, Nature reviews Drug discovery, vol.11, pp.191-200, 2012.

A. Mobley, S. K. Linder, R. Braeuer, L. M. Ellis, and Z. L. , A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic, PLoS One, vol.8, p.63221, 2013.

, ANNEXE 6. ARTICLE: CAN PENSION FUNDS PARTIALLY MANAGE LONGEVITY RISK BY INVESTING IN A LONGEVITY MEGAFUND?-184

, An analysis in 1995 of 500 life saving interventions suggested additional costs of 42 k$ per additional life-year but only 19 k$ for the specific case of medical interventions (see Tengs et al. (1995)). However, for cancer patients this number was 54k$ in 1995 and it ramped up to 217k$ in, with the ageing of populations (see Murphy and Topel, 2003.

. See-neumann, Based on all these numbers, we consider 50k$ as a reasonable accepted cost per life year gain, and since pharmaceutical companies would typically pay 40% of the value to the megafund, Elsewhere, 50k$ has long been the common reference and higher numbers are now often used, 2001.

P. Antolin and J. Mosher, Mortality Assumptions and Longevity Risk. Working Party on Private Pensions, 2014.

E. Arias, M. Heron, and B. Tejada-vera, United States Life Tables Eliminating Certain Causes of Death, Natl Vital Stat Rep, vol.61, issue.9, 1999.

S. Ayyadevara, A. R. Thaden, J. J. , S. Reis, and R. J. , Remarkable longevity and stress resistance of nematode PI3K-null mutants, Aging Cell, vol.7, issue.1, pp.13-22, 2008.

D. Barardo, D. Thornton, H. Thoppil, M. Walsh, S. Sharifi et al., The DrugAge database of aging-related drugs, vol.16, pp.594-597, 2017.

A. Bartke, M. Bonkowski, and M. Masternak, How diet interacts with longevity genes. Hormones, vol.7, pp.17-23, 2008.

M. S. Ben-haim, Y. Kanfi, S. J. Mitchel, N. Maoz, K. Vaughan et al., Breaking the Ceiling of Human Maximal Lifespan, J Gerontol A Biol Sci Med Sci, 2017.

F. H. Boissel, The cancer megafund: mathematical modeling needed to gauge risk, Nat Biotechnol, vol.31, issue.6, p.494, 2013.

J. Bongaarts, Long-Range Trends in Adult Mortality: Models and Projections Methods. Population Council, p.192, 2014.

J. Broadbent, M. Palumbo, and E. Woodman, The shift from defined benefit to defined contribution pension plans-implications for asset allocation and risk management. Reserve Bank of Australia, Board of Governors of the Federal Reserve System and Bank of Canada, pp.1-54, 2006.

G. Carbonnier, P. Chakraborty, D. Mulle, and E. , Asian and African Development Trajectories-Revisiting Facts and Figures. International Development Policy, Working Papers, 2013.

G. V. Casquillas, Human longevity : The giants. LongLongLife.org (web page), 2016.

, ANNEXE 6. ARTICLE: CAN PENSION FUNDS PARTIALLY MANAGE LONGEVITY RISK BY INVESTING IN A LONGEVITY MEGAFUND?-193

C. Registry, Tufts Medical Center Cost-Effectiveness Analysis

E. Debonneuil, Modèle paramétrique de mortalité en fonction de l'âge, pour des applications à des portefeuilles de retraite. Actuarial memorandum, 2015.

E. Debonneuil, F. Planchet, and S. Loisel, Do actuaries believe in longevity deceleration? Insurance: Mathematics and Economics, 2017.

E. Debonneuil, L. He, J. Mosher, and N. Weiss, Longevity Risk: Setting the scene, 2011.

N. Devlin, Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A discrete choice analysis, 2003.

J. A. Dimasi, R. W. Hansen, and H. Grabowski, The price of innovation: New estimates of drug development costs, Journal of Health Economics, vol.22, pp.151-185, 2003.

J. A. Dimasi, H. G. Grabowski, and R. W. Hansen, Innovation in the pharmaceutical industry: new estimates of R&D costs, Journal of health economics, vol.47, pp.20-33, 2016.

L. I. Dublin, Health and Wealth. A Survey of the Economics of World Health, p.361, 1928.

. Drugs@fda, , 2018.

. Evaluate, FDA Approval Rates, 2013.

G. M. Fahy, Apparent induction of partial thymic regeneration in a normal human subject: a case report, J Anti-Aging Med, vol.6, issue.3, pp.219-227, 2003.

D. E. Fagnan, A. A. Gromatzky, R. M. Stein, J. M. Fernandez, and A. W. Lo, Financing drug discovery for orphan diseases. Drug discovery today, vol.19, pp.533-538, 2014.

D. E. Fagnan, N. N. Yang, J. C. Mckew, and A. W. Lo, Financing translation: Analysis of the NCATS rarediseases portfolio, Science translational medicine, vol.7, issue.276, pp.276-279, 2015.

J. M. Fernandez, R. M. Stein, and A. W. Lo, Commercializing biomedical research through securitization techniques, Nature biotechnology, vol.30, pp.964-975, 2012.

L. P. Freedman, I. M. Cockburn, and T. S. Simcoe, The economics of reproducibility in preclinical research, vol.13, p.1002165, 2015.

L. A. Gavrilov, V. N. Krut&apos;ko, and N. S. Gavrilova, The future of human longevity, vol.63, pp.524-526, 2017.

Q. Guibert, F. Planchet, and M. Schwarzinger, Mesure de l'espérance de vie sans dépendance en France, 2017.

L. Heligman and J. H. Pollard, The age pattern of mortality, Journal of the Institute of Actuaries, vol.107, issue.1, pp.49-82, 1980.

, ANNEXE 6. ARTICLE: CAN PENSION FUNDS PARTIALLY MANAGE LONGEVITY RISK BY INVESTING IN A LONGEVITY MEGAFUND?-194

, Defined benefit pension schemes, House of Commons Work and Pensions Committee, pp.2016-2033, 2016.

D. H. Howard, P. B. Bach, E. R. Berndt, and R. M. Conti, Pricing in the market for anticancer drugs, Journal of Economic Perspectives, vol.29, issue.1, pp.139-62, 2015.

J. Hull, Funding long shots. Rotman School of Management Working Paper No. 2773108, 2016.

R. N. Kahn, A Simple Hedge for Longevity Risk using Research-Backed Obligations. JOIM Conference, 2015.

N. El-karoui, M. Mrad, and C. Hillairet, Affine long-term yield curves: An application of the Ramsey rule with progressive utility, Journal of Financial Engineering, vol.1, issue.1, 2014.

A. Kamega, F. Planchet, and P. E. Thérond, Scénarios économiques en assurance-Modélisation et simulation, 2009.

E. D. Kantor, C. D. Rehm, J. S. Haas, A. T. Chan, and E. L. Giovannucci, Trends in prescription drug use among adults in the United States from, Jama, vol.314, issue.17, pp.1818-1830, 1999.

C. J. Kenyon, The genetics of ageing, Nature, vol.464, issue.7288, p.504, 2010.

W. Lazonick, M. Hopkins, K. Jacobson, M. E. Sakinc, and O. Tulum, US Pharma's Financialized Business Model, 2017.

R. D. Lee and C. L. , Modeling and forecasting U.S. mortality, Journal of the American Statistical Association, vol.87, pp.659-671, 1992.

F. R. Lichtenberg, P. Grootendorst, M. Van-audenrode, D. Latremouille-viau, and P. Lefebvre, The Impact of Drug Vintage on Patient Survival: A Patient-Level Analysis Using Quebec's Provincial Health Plan Data, Value in Health, vol.12, issue.6, pp.847-856, 2009.

F. R. Lichtenberg, Pharmaceutical innovation and longevity growth in 30 developing and highincome countries, Health Policy and Technology, vol.3, issue.1, pp.36-58, 2000.

F. R. Lichtenberg, M. Tatar, and Z. Çal??kan, The impact of pharmaceutical innovation on health outcomes and utilization in Turkey: A re-examination. Health policy and technology, vol.6, pp.226-233, 2017.

D. W. Light and R. Warburton, Demythologizing the high costs of pharmaceutical research, BioSocieties, vol.6, issue.1, pp.34-50, 2011.

A. W. Lo, C. Ho, J. Cummings, and K. S. Kosik, Parallel discovery of Alzheimer's therapeutics, Science translational medicine, vol.6, issue.241, pp.241-246, 2014.

A. W. Lo, Can Financial Engineering Cure Cancer, 2015.

A. W. Lo and S. V. Naraharisetti, New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, vol.12, pp.4-19, 2014.

R. D. Macminn and N. Zhu, Hedging Longevity Risk in Life Settlements Using Biomedical Research-Backed Obligations, Journal of Risk and Insurance, vol.84, issue.1, pp.439-458, 2017.

, ANNEXE 6. ARTICLE: CAN PENSION FUNDS PARTIALLY MANAGE LONGEVITY RISK BY INVESTING IN A LONGEVITY MEGAFUND?-195

J. P. De-magalhães, M. Stevens, and D. Thornton, The business of anti-aging science, Trends in biotechnology, 2017.

N. F. Marko, The cancer megafund: determinants of success, Nat Biotechnol, vol.31, issue.6, pp.492-496, 2013.

G. M. Martin, K. Lamarco, E. Strauss, and K. Kelner, Research on aging: the end of the beginning, vol.299, 2003.

L. Martin, M. Hutchens, C. Hawkins, and A. Radnov, How much do clinical trials cost?, Nature reviews. Drug discovery, vol.16, issue.6, p.381, 2017.

J. Mellon and A. Chalabi, Juvenescence: Investing in the age of longevity, 2017.

A. R. Mendelsohn, J. W. Larrick, and J. L. Lei, Rejuvenation by Partial Reprogramming of the Epigenome, Rejuvenation Res, vol.20, issue.2, pp.146-150, 2017.

T. A. Mir and M. Nakamura, Three-Dimensional Bioprinting: Toward the Era of Manufacturing Human Organs as Spare Parts for Healthcare and Medicine, Tissue Eng Part B Rev, vol.23, issue.3, pp.245-256, 2017.

A. Moskalev, V. Anisimov, A. Aliper, A. Artemov, K. Asadullah et al., A review of the biomedical innovations for healthy longevity, vol.9, pp.7-25, 2017.

L. Mosteiro, C. Pantoja, N. Alcazar, R. M. Marión, D. Chondronasiou et al., Tissue damage and senescence provide critical signals for cellular reprogramming in vivo, Science, vol.354, issue.6315, 2016.

K. M. Murphy and R. H. Topel, The value of health and longevity, Journal of political Economy, vol.114, issue.5, pp.871-904, 2006.

P. J. Neumann, J. T. Cohen, and M. C. Weinstein, Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold, New England Journal of Medicine, vol.371, issue.9, pp.796-797, 2014.

A. Ocampo, P. Reddy, P. Martinez-redondo, A. Platero-luengo, F. Hatanaka et al., Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell, vol.167, pp.1719-1733, 2016.

, Health at a Glance : OECD Indicators, OECD, 2017.

S. J. Olshansky, B. A. Carnes, and C. Cassel, Search of Methuselah: Estimating the Upper Limits to Human Longevity, vol.250, p.4981, 1990.

L. Phalippou, Investing in Private Equity Funds: A Survey. The Research Foundation of CFA Institute, 2010.

F. Pifferi, J. Terrien, J. Marchal, A. Dal-pan, F. Djelti et al., Caloric restriction increases lifespan but affects brain integrity in grey mouse lemur primates, Communications Biology, vol.1, issue.1, p.30, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01912059

P. Planchet and P. E. Thérond, Allocation d'actifs selon le critère de maximisation des fonds propres économiques en assurance non-vie : présentation et mise en oeuvre dans la réglementation française et dans un référentiel de type Solvabilité 2, Bulletin Français d'Actuariat, vol.7, issue.13, 2007.

C. Pratt, 5 Private Longevity Stocks to Watch: From Calico to Genescient, 2016.

D. J. Ravnic, A. N. Leberfinger, S. V. Koduru, M. Hospodiuk, K. K. Moncal et al., Transplantation of Bioprinted Tissues and Organs: Technical and Clinical Challenges and Future Perspectives, Ann Surg, vol.266, issue.1, pp.48-58, 2017.

P. Román and A. Ruiz-cantero, Polypathology, an emerging phenomenon and a challenge for healthcare systems, Rev Clin Esp, vol.217, issue.4, pp.229-237, 2017.

A. Sertkaya, H. H. Wong, A. Jessup, and T. Beleche, Key cost drivers of pharmaceutical clinical trials in the United States, Clinical Trials, vol.13, issue.2, pp.117-126, 2016.

J. W. Scannell, A. Blanckley, H. Boldon, and B. Warrington, Diagnosing the decline in pharmaceutical R&D efficiency, Nature reviews Drug discovery, vol.11, pp.191-200, 2012.

R. M. Stein, A Simple Hedge for Longevity Risk and Reimbursement Risk Using Research-Backed Obligations, MIT Sloan Research Paper, pp.5165-5181, 2016.

J. J. Stewart, P. N. Allison, and R. S. Johnson, Putting a price on biotechnology, Nature biotechnology, vol.19, issue.9, p.813, 2001.

, Towards a Swedish megafund for life science innovation, Swedish Agency for Growth Policy Analysis, 2017.

J. M. Tenenbaum, The cancer megafund: a catalyst for disruptive innovation, Nat Biotechnol, vol.31, issue.6, pp.491-493, 2013.
DOI : 10.1038/nbt.2605

URL : http://sciencecommons.org/wp-content/uploads/health-commons-whitepaper-launch.pdf

T. O. Tengs, M. E. Adams, J. S. Pliskin, D. G. Safran, J. E. Siegel et al., Five-hundred life-saving interventions and their cost-effectiveness, ANNEXE 6. ARTICLE: CAN PENSION FUNDS PARTIALLY MANAGE LONGEVITY RISK BY INVESTING IN A LONGEVITY MEGAFUND?-197, vol.15, pp.369-390, 1995.
DOI : 10.1111/j.1539-6924.1995.tb00330.x

U. Thiem, T. Hinrichs, C. A. Müller, S. Holt-noreiks, A. Nagl et al., Prerequisites for a new health care model for elderly people with multiple morbidities: results and conclusions from 3 years of research in the PRISCUS consortium, Z Gerontol Geriatr, vol.44, issue.2, pp.101-113, 2011.

F. A. Thiers, A. J. Sinskey, and E. R. Berndt, Trends in the globalization of clinical trials, 2008.

D. W. Thomas, J. Burns, J. Audette, C. A. Dow-hygelund, C. Hay et al., Clinical Development Success Rates, 2006.

. Transparency-market-research, Anti-aging Market (Anti-wrinkle products, Hair Color, Hair restoration treatment, Breast augmentation and Radio frequency devices)-Global Industry Analysis, Size, Share, Growth, Trends and Forecast, pp.2013-2019, 2014.

. Ue-commission, supplementing Directive 2009/138/EC of the European Parliament and of the Council on the taking-up and pursuit of the business of Insurance and Reinsurance (Solvency II) US Department of Labor, COMMISSION DELEGATED REGULATION (EU) 2015/35 of 10 October, 2014.

J. Vallin and F. Meslé, Espérance de vie: peut-on gagner trois mois par an indéfiniment?, p.473, 2010.

J. W. Vaupel, Biodemography of human ageing, Nature, vol.464, issue.7288, pp.536-578, 2010.
DOI : 10.1038/nature08984

URL : http://europepmc.org/articles/pmc4010874?pdf=render

C. H. Wong, K. W. Siah, and A. W. Lo, Estimate of clinical trial success rates and related parameters, Biostatistics, 2018.

X. Yang, E. Debonneuil, A. Zhavoronkov, and B. Mishra, Cancer megafunds with in silico and in vitro validation: Accelerating cancer drug discovery via financial engineering without financial crisis, Oncotarget, 2016.
DOI : 10.18632/oncotarget.9808

URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=9808&path%5B%5D=30784

A. Zhavoronkov, E. Debonneuil, N. Mirza, and I. Artyuhov, Evaluating the impact of recent advances in biomedical sciences and the possible mortality decreases on the future of health care and Social Security in the United States. Pensions, vol.17, pp.241-251, 2012.

, Anti-Stretch Mark Products, and Others), by Services (AntiPigmentation Therapy, Anti-Adult Acne Therapy, Breast Augmentation, Liposuction, Chemical Peel, Hair Restoration Treatment, and Others), by Device (Microdermabrasion, Laser Aesthetics, AntiCellulite Treatment and Anti-Aging Radio Frequency Devices) : Global Industry Perspective, Anti-Aging Market (Baby Boomer, Generation X and Generation Y), by product (Botox, Anti-Wrinkle Products, pp.2015-2021, 2017.